U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H22O2
Molecular Weight 282.3768
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VEDAPROFEN

SMILES

CC(C(O)=O)C1=CC=C(C2CCCCC2)C3=CC=CC=C13

InChI

InChIKey=VZUGVMQFWFVFBX-UHFFFAOYSA-N
InChI=1S/C19H22O2/c1-13(19(20)21)15-11-12-16(14-7-3-2-4-8-14)18-10-6-5-9-17(15)18/h5-6,9-14H,2-4,7-8H2,1H3,(H,20,21)

HIDE SMILES / InChI
Molecular Formula C19H22O2
Molecular Weight 282.3768
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Vedaprofen is a PGE2 synthase inhibitor approved in Europe for the treatment of pain in horses and dogs.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Prostaglandin G/H synthase 2
51
Target ID: O19183
Gene ID: 791253.0
Gene Symbol: PTGS2
Target Organism: Equus caballus (Horse)
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
QUADRISOL

Approved Use

Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).

Launch Date

1997
PubMed

PubMed

TitleDatePubMed
Treatment of persistent mating-induced endometritis in mares with the non-steroid anti-inflammatory drug vedaprofen.
2010-12
Practical experience with the treatment of recipient mares with a non-steroidal anti-inflammatory drug in an equine embryo transfer programme.
2010-12
Analgesic efficacy of perioperative use of vedaprofen, tramadol or their combination in cats undergoing ovariohysterectomy.
2009-06
Perioperative administration of vedaprofen, tramadol or their combination does not interfere with platelet aggregation, bleeding time and biochemical variables in cats.
2009-06
Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs.
2008-02
Vedaprofen therapy in cats with upper respiratory tract infection or following ovariohysterectomy.
2007-02
Influence of vedaprofen (Quadrisol) on quality and freezability of stallion semen.
2005-11
The pharmacokinetics of vedaprofen and its enantiomers in dogs after single and multiple dosing.
2005-06
Comparison of vedaprofen and meloxicam in dogs with musculoskeletal pain and inflammation.
2002-05

Sample Use Guides

In Vivo Use Guide
Twice daily administration. An initial dose of 2 mg/kg (2.0 ml/100 kg) is followed by a maintenance dose of 1 mg/kg (1.0 ml/100 kg) given every 12 hours. Treatment can be continued for a maximum of 14 consecutive days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:33:02 GMT 2025
Edited
by admin
on Mon Mar 31 18:33:02 GMT 2025
Record UNII
OKX88EO7OI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VEDAPROFEN FOR VETERINARY USE
EP  
Preferred Name English
VEDAPROFEN
INN   JAN   MART.   MI   USAN  
INN   USAN  
Official Name English
CERM10202
Code English
1-NAPHTHALENEACETIC ACID, 4-CYCLOHEXYL-.ALPHA.-METHYL-, (±)-
Common Name English
VEDAPROFEN [MI]
Common Name English
CERM-10202
Code English
VEDAPROFEN [JAN]
Common Name English
1-NAPHTHALENEACETIC ACID, 4-CYCLOHEXYL-.ALPHA.-METHYL-
Common Name English
VEDAPROFEN [EMA EPAR VETERINARY]
Common Name English
vedaprofen [INN]
Common Name English
VEDAPROFEN [USAN]
Common Name English
VEDAPROFEN FOR VETERINARY USE [EP MONOGRAPH]
Common Name English
PM-150
Code English
QUADRISOL
Brand Name English
PM150
Code English
VEDAPROFEN [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QM01AE90
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS QUADRISOL [AUTHORIZED]
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
NCI_THESAURUS C257
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
Code System Code Type Description
INN
7298
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
MERCK INDEX
m11403
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY Merck Index
CHEBI
32292
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
NCI_THESAURUS
C66652
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
SMS_ID
100000079096
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
EPA CompTox
DTXSID5049077
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
CAS
71109-09-6
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
WIKIPEDIA
VEDAPROFEN
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
DRUG CENTRAL
2812
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
PUBCHEM
72158
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104464
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
USAN
GG-7
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
FDA UNII
OKX88EO7OI
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
EVMPD
SUB00031MIG
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
ECHA (EC/EINECS)
275-196-6
Created by admin on Mon Mar 31 18:33:02 GMT 2025 , Edited by admin on Mon Mar 31 18:33:02 GMT 2025
PRIMARY
Related Record Type Details
Structure of VEDAPROFEN, (R)-
ENANTIOMER -> RACEMATE
Structure of VEDAPROFEN MEGLUMINE
SALT/SOLVATE -> PARENT
Structure of VEDAPROFEN, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of VEDAPROFEN
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966